Table 2.
Some selected immunotherapeutic agents (Anti- PD-1) in clinical trials including the possible combination therapy.
| CT Number | Status | Phase | Condition | Sponsor | Additional agents |
|---|---|---|---|---|---|
| PIDILIZUMAB (CT001) (ANTI-PD-1) | |||||
| NCT02530125 | Active, not recruiting | II | Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma | Northwestern University; Gateway for Cancer Research; National Cancer Institute (NCI) | – |
| NCT02077959 | Active, not recruiting | I/II | Multiple Myeloma | Yvonne Efebera; CureTech Ltd; Ohio St. Univ. Comprehensive Cancer Center | lenalidomide |
| NCT00532259 | Completed | III | Lymphoma, Large Cell, Diffuse; Lymphoma, Mixed Cell, Diffuse; Primary Mediastinal Large B-Cell Lymphoma | Cure Tech Ltd | – |
| NCT01435369 | Completed | II | Melanoma; Malignant Melanoma | Medivation, Inc. | – |
| NCT00532259 | Completed | II | Lymphoma, Large Cell, Diffuse; Lymphoma, Mixed Cell, Diffuse; Primary Mediastinal Large B-Cell Lymphoma | CureTech Ltd | – |
| NCT00890305 | Completed | II | Metastatic Colorectal Cancer | Medivation, Inc. | FOLFOX |
| NCT02077959 | Active, not recruiting | II | Multiple Myeloma | Yvonne Efebera; CureTech Ltd; Ohio State University Comprehensive Cancer Center | Lenalidomide, pidilizumab |
| NCT02530125 | Active, not recruiting | II | Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma | Northwestern University; Gateway for Cancer Research; National Cancer Institute (NCI) | Pidilizumab |
| REGN2810 (ANTI-PD-1) | |||||
| NCT03002376 | Not yet recruiting | II | Melanoma | Regeneron Pharmaceuticals; Sanofi | – |
| NCT02760498 | Recruiting | II | Advanced Cutaneous Squamous Cell Carcinoma | Regeneron Pharmaceuticals | – |
| AMP-224 (ANTI-PD-1) | |||||
| NCT02298946 | Active, not recruiting | I | Colorectal Cancer; Colorectal Neoplasms; Colorectal Carcinoma | National Cancer Institute (NCI); National Institutes of Health Clinical Center (CC) | Cyclophosphamide |
| NCT01352884 | Completed | I | Cancer | MedImmune LLC; GlaxoSmithKline | – |
| MEDI0680 (ANTI-PD-1) | |||||
| NCT02118337 | Recruiting | I | Select Advanced Malignancies | MedImmune LLC | MEDI4736 |
| NCT02013804 | Active, not recruiting | I | Advanced Malignancies | MedImmune LLC | – |
| NCT02271945 | Completed | I | Relapsed/Refractory Aggressive B-cell Lymphomas | MedImmune LLC | MEDI-551 |
| PDR001 (ANTI-PD-1) | |||||
| NCT02678260 | Active, not recruiting | I | Advanced Malignancies | Novartis Pharmaceuticals | |
| NCT02795429 | Recruiting | I | Advanced Hepatocellular Carcinoma | Novartis Pharmaceuticals | INC280 |
| NCT02404441 | Recruiting | I | Melanoma; NSCLC; TNBC; Anaplastic Thyroid Cancer; Other Solid Tumors | Novartis Pharmaceuticals | |
| NCT02605967 | Recruiting | II | Nasopharyngeal Carcinoma | Novartis Pharmaceuticals | |
| NCT02947165 | Not yet recruiting | I | Breast Cancer; Lung Cancer; Hepatocellular Cancer; Colorectal Cancer; Pancreatic Cancer; Prostate Cancer; Renal Cancer | Novartis Pharmaceuticals | NIS793 |
| NCT02829723 | Recruiting | I | Advanced Solid Tumors | Novartis Pharmaceuticals | BLZ945 |
| NCT02936102 | Recruiting | I | Advanced Solid Tumors; NSCLC; TNBC; Endometrial Cancer; Anaplastic Thyroid Cancer | Novartis Pharmaceuticals | FAZ053 |
| NCT02988440 | Not yet recruiting | I | Hepatocellular Carcinoma | Novartis Pharmaceuticals | Sorafenib |
| NCT02608268 | Recruiting | I | Advanced Malignancies | Novartis Pharmaceuticals | MBG453 |
| NCT02460224 | Recruiting | I | Advanced Solid Tumors | Novartis Pharmaceuticals | LAG525 |
| NCT02403193 | Recruiting | I | NSCLC | Palobiofarma SL; Novartis; H. Lee Moffitt Cancer Center and Research Institute | PBF-509 |
| NCT02807844 | Recruiting | I | TNBC; Pancreatic Carcinoma; Melanoma; Endometrial Carcinoma | Novartis Pharmaceuticals | MCS110 |
| NCT02740270 | Recruiting | I | Solid Tumors; Lymphomas | Novartis Pharmaceuticals | GWN323 |
| NCT02967692 | Not yet recruiting | III | Melanoma | Novartis Pharmaceuticals | Dabrafenib, Trametinib |
| NCT02890069 | Recruiting | I | Colorectal Cancer; NSCLC(Adenocarcinoma); TNBC | Novartis Pharmaceuticals | LCL161, Everolimus, Panobinostat |
| NCT02900664 | Recruiting | I | Colorectal Cancer; TNBC; NSCLC(Adenocarcinoma) | Novartis Pharmaceuticals | ACZ885, CJM112, TMT212, EGF816 |
| NCT02325739 | Recruiting | I | HCC | Novartis Pharmaceuticals | FGF401 |
| NCT02607813 | Recruiting | I | NSCLC; Ovarian Cancer; Melanoma; Other Solid Tumors | Novartis Pharmaceuticals; Novartis | LXH254 |
Data taken from Clinicaltrials.gov website.